Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Baseline Demographic, Clinical, Laboratory Characteristics, and Medications of Patients. Variable | Total (N = 1594) | PTH ≤ 82 (N = 1150) | PTH > 82 (N = 444) | p Value: Vitamin D, µg/L | 19 (13.1 to 27) | 20.3(14.3 to 28.0) | 15.6 (10.5 to 23.0) | <0.001

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This retrospective, single-center cohort study was conducted at the Antalya Training and Research Hospital, Department of Cardiology.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Prognostic Value of Parathyroid Hormone in Heart Failure with Reduced Ejection Fraction

Cohort study · Journal of Clinical Medicine · 2026

Original publication title

Prognostic Value of Parathyroid Hormone in Heart Failure with Reduced Ejection Fraction

Ahmet Genç; Gülsüm Meral Yılmaz Öztekin; Şükriye Uslu; Rauf Avcı

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background/Objectives:

Parathyroid hormone (PTH) has emerged as a novel biomarker in heart failure (HF), reflecting neurohormonal, renal, and metabolic dysregulation within the cardiorenal: mineral axis. However, its independent prognostic value and incremental contribution remain unclear when evaluated through formal nested structures Therefore, this study aimed to evaluate the association between PTH and all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF) and to determine whether PTH provides additional prognostic information beyond NT-proBNP.

Methods:

In this retrospective cohort study, 1594 patients with HFrEF (LVEF ≤ 40%) were analyzed. Serum PTH and NT-proBNP levels were log-transformed and evaluated as predictors of all-cause mortality. Patients were stratified according to PTH levels, and survival analysis was performed. Incremental model fit was evaluated using nested likelihood ratio tests. Stratified multivariable Cox models and formal interaction tests were executed across predefined clinical strata (age, renal function, and heart failure etiology).

Results:

During a median follow-up of 36 months, 525 deaths occurred. Elevated PTH levels were associated with worse survival outcomes. In multivariable Cox regression analysis, both LnPTH (HR: 1.233, p = 0.0147) and LnNT-proBNP (HR: 1.374, p < 0.0001) were independent predictors of mortality. Combined elevation of PTH and NT-proBNP identified patients at the highest risk. The addition of LnPTH to the baseline model significantly improved global model fit (χ2 = 4.242, p = 0.0394). Importantly, the prognostic value of LnPTH was significantly modified by age (Pinteraction = 0.026) and renal function (Pinteraction = 0.038), demonstrating independent predictive power specifically in patients aged < 65 years (HR: 1.402) and those with eGFR ≥ 60 mL/min/1.73 m2 (HR: 1.454), but not in older or advanced renal impairment strata.

Conclusions:

PTH is independently associated with mortality in patients with HFrEF and provides incremental prognostic value beyond NT-proBNP by optimizing global model fit. These findings support its role as a complementary biomarker within a multimarker strategy for improved risk stratification of the cumulative metabolic and cardiovascular burden.

An extract from the source publication. Read it in context.

At a glance

Abstract: Background/Objectives

Parathyroid hormone (PTH) has emerged as a novel biomarker in heart failure (HF), reflecting neurohormonal, renal, and metabolic dysregulation within the cardiorenal: mineral axis. However, its independent prognostic value and incremental contribution remain unclear when evaluated through formal nested structures Therefore, this study aimed to evaluate the association between PTH and all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF) and to determine whether PTH provides additional prognostic information beyond NT-proBNP.

Source: Background/Objectives

Abstract: Results

During a median follow-up of 36 months, 525 deaths occurred. Elevated PTH levels were associated with worse survival outcomes. In multivariable Cox regression analysis, both LnPTH (HR: 1.233, p = 0.0147) and LnNT-proBNP (HR: 1.374, p < 0.0001) were independent predictors of mortality. Combined elevation of PTH and NT-proBNP identified patients at the highest risk. The addition of LnPTH to the baseline model significantly improved global model fit (χ2 = 4.242, p = 0.0394). Importantly, the prognostic value of LnPTH was significantly modified by age (Pinteraction = 0.026) and renal function (Pinteraction = 0.038), demonstrating independent predictive power specifically in patients aged < 65 years (HR: 1.402) and those with eGFR ≥ 60 mL/min/1.73 m2 (HR: 1.454), but not in older or advanced renal impairment strata.

Source: Results

Abstract: Conclusions

PTH is independently associated with mortality in patients with HFrEF and provides incremental prognostic value beyond NT-proBNP by optimizing global model fit. These findings support its role as a complementary biomarker within a multimarker strategy for improved risk stratification of the cumulative metabolic and cardiovascular burden.

Source: Conclusions
Authors’ abstract

Background/Objectives:

Parathyroid hormone (PTH) has emerged as a novel biomarker in heart failure (HF), reflecting neurohormonal, renal, and metabolic dysregulation within the cardiorenal: mineral axis. However, its independent prognostic value and incremental contribution remain unclear when evaluated through formal nested structures Therefore, this study aimed to evaluate the association between PTH and all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF) and to determine whether PTH provides additional prognostic information beyond NT-proBNP.

Methods:

In this retrospective cohort study, 1594 patients with HFrEF (LVEF ≤ 40%) were analyzed. Serum PTH and NT-proBNP levels were log-transformed and evaluated as predictors of all-cause mortality. Patients were stratified according to PTH levels, and survival analysis was performed. Incremental model fit was evaluated using nested likelihood ratio tests. Stratified multivariable Cox models and formal interaction tests were executed across predefined clinical strata (age, renal function, and heart failure etiology).

Results:

During a median follow-up of 36 months, 525 deaths occurred. Elevated PTH levels were associated with worse survival outcomes. In multivariable Cox regression analysis, both LnPTH (HR: 1.233, p = 0.0147) and LnNT-proBNP (HR: 1.374, p < 0.0001) were independent predictors of mortality. Combined elevation of PTH and NT-proBNP identified patients at the highest risk. The addition of LnPTH to the baseline model significantly improved global model fit (χ2 = 4.242, p = 0.0394). Importantly, the prognostic value of LnPTH was significantly modified by age (Pinteraction = 0.026) and renal function (Pinteraction = 0.038), demonstrating independent predictive power specifically in patients aged < 65 years (HR: 1.402) and those with eGFR ≥ 60 mL/min/1.73 m2 (HR: 1.454), but not in older or advanced renal impairment strata.

Conclusions:

PTH is independently associated with mortality in patients with HFrEF and provides incremental prognostic value beyond NT-proBNP by optimizing global model fit. These findings support its role as a complementary biomarker within a multimarker strategy for improved risk stratification of the cumulative metabolic and cardiovascular burden.

Publication and source details

Original title: Prognostic Value of Parathyroid Hormone in Heart Failure with Reduced Ejection Fraction

Ahmet Genç; Gülsüm Meral Yılmaz Öztekin; Şükriye Uslu; Rauf Avcı

Journal of Clinical Medicine · 2026

* Correspondence: ahmet.genc6@saglik.gov.tr© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no external funding. The APC was funded by the authors themselves.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:15:36.154600+00:00

DOI: 10.3390/jcm15134859 · PMC13361963